Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Bettering China's biosimilars

Henlius, Innovent represent new breed of biosimilars companies in China

March 18, 2013 7:00 AM UTC

While many homegrown biologics marketed in China could be perceived as biosimilars, most are unlikely to meet international standards and are not marketed as such in China. But with an uptick in returnees and VC investment, and improvement in manufacturing infrastructure, Chinese companies such as Henlius Biotech Co. Ltd. and Innovent Biologics Inc. are aiming to develop true biosimilars that could compete in the global market.

Current regulations in the EU and U.S. require a biosimilar to have the same amino acid sequence as the innovator biologic, and glycosylation patterns and other structural features that are highly similar, so that the two products closely match in terms of efficacy and safety...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article